TY - JOUR
T1 - Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy
AU - Quattrocelli, Mattia
AU - Zelikovich, Aaron S.
AU - Salamone, Isabella M.
AU - Fischer, Julie A.
AU - McNally, Elizabeth M.
N1 - Funding Information:
Supported by NIH U54 AR052646, NIH RO1 NS047726, NIH F31 AR073655 (IMS), American Heart Association 20PRE35210837 (JAF), the Parent Project for Muscular Dystrophy. MQ is supported by NIH K01 DK121875 (NIDDK).
Publisher Copyright:
© 2021 - The authors. Published by IOS Press.
PY - 2021
Y1 - 2021
N2 - Glucocorticoid steroids are widely used as immunomodulatory agents in acute and chronic conditions. Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy. Despite this benefit, glucocorticoid use in Duchenne Muscular Dystrophy is also associated with significant adverse consequences including adrenal suppression, growth impairment, poor bone health and metabolic syndrome. For other forms of muscular dystrophy like the limb girdle dystrophies, glucocorticoids are not typically used. Here we review the experimental evidence supporting multiple mechanisms of glucocorticoid action in dystrophic muscle including their role in dampening inflammation and myofiber injury. We also discuss alternative dosing strategies as well as novel steroid agents that are in development and testing, with the goal to reduce adverse consequences of prolonged glucocorticoid exposure while maximizing beneficial outcomes.
AB - Glucocorticoid steroids are widely used as immunomodulatory agents in acute and chronic conditions. Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy. Despite this benefit, glucocorticoid use in Duchenne Muscular Dystrophy is also associated with significant adverse consequences including adrenal suppression, growth impairment, poor bone health and metabolic syndrome. For other forms of muscular dystrophy like the limb girdle dystrophies, glucocorticoids are not typically used. Here we review the experimental evidence supporting multiple mechanisms of glucocorticoid action in dystrophic muscle including their role in dampening inflammation and myofiber injury. We also discuss alternative dosing strategies as well as novel steroid agents that are in development and testing, with the goal to reduce adverse consequences of prolonged glucocorticoid exposure while maximizing beneficial outcomes.
KW - Glucocorticoid steroids
KW - immunomodulation
KW - metabolism
KW - molecular signaling
KW - muscle physiology
KW - muscular dystrophy
KW - neuromuscular diseases
UR - http://www.scopus.com/inward/record.url?scp=85098712881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098712881&partnerID=8YFLogxK
U2 - 10.3233/JND-200556
DO - 10.3233/JND-200556
M3 - Review article
C2 - 33104035
AN - SCOPUS:85098712881
SN - 2214-3599
VL - 8
SP - 39
EP - 52
JO - Journal of Neuromuscular Diseases
JF - Journal of Neuromuscular Diseases
IS - 1
ER -